| 1391 |
National Cancer Institute |
Html |
en |
Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of Wilms tumor. |
| wilms tumors | 0.503727 |
| wilms tumor | 0.905843 |
| Wilms tumor development | 0.5254 |
| Wilms tumor genetics | 0.517912 |
| Wilms Tumor Study-5 | 0.477443 |
| familial Wilms tumour | 0.446601 |
| favorable-histology wilms tumor | 0.511105 |
| stage II Wilms | 0.439212 |
| unilateral Wilms tumor | 0.553115 |
| Wilms tumor patients | 0.529584 |
| favorable histology Wilms | 0.460427 |
| bilateral Wilms patients | 0.460054 |
| Tumor Study Group | 0.595101 |
| contralateral Wilms tumor | 0.495745 |
| Wilms tumor-Aniridia syndrome | 0.439108 |
| preoperative wilms tumor | 0.505524 |
| bilateral wilms tumor | 0.635902 |
| stromal-type Wilms tumor | 0.516983 |
| Wilms tumor surveillance | 0.49553 |
| beckwith-wiedemann syndrome | 0.43423 |
| inoperable Wilms tumor | 0.526248 |
| Group/National Wilms Tumor | 0.47873 |
| Low-risk Wilms Tumor | 0.474612 |
| histology Wilms tumors | 0.433526 |
| Wilms Tumor Study | 0.723902 |
|
| Wilms tumor screening | 0.479856 |
| wilms tumor rupture | 0.501052 |
| et al. | 0.499553 |
| wilms tumor predisposition | 0.521351 |
| histology Wilms tumor | 0.504567 |
| Wilms tumours | 0.453209 |
| COG Wilms tumor | 0.518219 |
| SIOP Wilms Tumor | 0.504401 |
| Wilms tumour | 0.50015 |
| bilateral Wilms tumor. | 0.45063 |
| Pediatr Blood Cancer | 0.440629 |
| wilms tumor suppressor | 0.492641 |
| nonsyndromic Wilms tumor | 0.493832 |
| Metachronous bilateral Wilms | 0.434751 |
| National Wilms Tumor | 0.736085 |
| Med Genet | 0.447601 |
| Abstract | 0.531043 |
| Clin Oncol | 0.453706 |
| familial Wilms tumor. | 0.444435 |
| Wilms tumor locus | 0.521817 |
| Familial Wilms tumor | 0.495658 |
| non-WT1-syndromic Wilms tumor | 0.488494 |
| Wilms Tumor Study-3 | 0.478135 |
| Wilms tumor susceptibility | 0.497583 |
|
CLICK HERE |
| 1528 |
National Cancer Institute |
Html |
en |
Ovarian Low Malignant Potential Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of ovarian low-malignant potential tumors. |
| currently used treatment | 0.491433 |
| treatment | 0.80031 |
| abnormal cells | 0.591776 |
| cancer treatment | 0.491469 |
| ovaries | 0.553108 |
| abdomen | 0.566902 |
| body cavity | 0.495458 |
| NCI-supported cancer | 0.497228 |
| tissue | 0.516419 |
| cancer cells | 0.493195 |
| body | 0.515176 |
| Cancer Information Service | 0.489344 |
| low malignant potential | 0.507879 |
| PDQ cancer information | 0.620272 |
| clinical trial search | 0.566415 |
| uterus | 0.498028 |
| treatment clinical trials | 0.555055 |
| National Cancer Institute | 0.572253 |
| clinical trials | 0.964888 |
| tumor cells | 0.695966 |
| Treatment Options section | 0.484079 |
| cancer information summary | 0.567078 |
| clinical trial | 0.741404 |
| new treatment | 0.564234 |
|
| disease | 0.554973 |
| malignant potential tumor | 0.900634 |
| new treatments | 0.489278 |
| patients | 0.603036 |
| earlier clinical trials | 0.497766 |
| clinical trials database | 0.496798 |
| peritoneal cavity | 0.517264 |
| Potential Tumors Treatment | 0.491558 |
| treatment clinical trial | 0.511947 |
| PDQ Adult Treatment | 0.504736 |
| NCI PDQ cancer | 0.507801 |
| ovary | 0.536161 |
| cancer clinical trials | 0.578107 |
| tests | 0.498811 |
| stage | 0.7416 |
| malignant potential tumors | 0.621847 |
| fallopian tubes | 0.57444 |
| treatment options | 0.549139 |
| Treatment Editorial Board | 0.533517 |
| cancer information summaries | 0.487894 |
| comprehensive cancer information | 0.488381 |
| cancer | 0.721628 |
| standard treatment | 0.552748 |
|
CLICK HERE |
| 1712 |
National Cancer Institute |
Html |
en |
Antioxidants and Cancer Prevention |
A fact sheet about antioxidants, substances that may protect cells from the damage caused by unstable molecules known as free radicals. Free radical damage may lead to cancer. |
| Nutrition Intervention Trial | 0.501895 |
| esophageal cancer | 0.494202 |
| cancer prevention | 0.637226 |
| dietary antioxidant supplements | 0.628093 |
| Retinol Efficacy Trial | 0.539912 |
| antioxidants | 0.567107 |
| supplementation | 0.636543 |
| beta-carotene supplementation | 0.609246 |
| vitamin E supplementation | 0.519408 |
| randomized controlled trials | 0.504401 |
| trial | 0.573618 |
| daily supplementation | 0.567334 |
| lung cancer | 0.591669 |
| Alpha-Tocopherol/Beta-Carotene Cancer Prevention | 0.499391 |
| Health Study | 0.544001 |
| free radical damage | 0.506138 |
| beta-carotene supplements | 0.507967 |
| National Cancer Institute | 0.710208 |
| dietary antioxidants | 0.513132 |
| beta carotene | 0.496454 |
| cardiovascular disease | 0.651531 |
| Cancer Prevention Study | 0.537001 |
| Vitamin E Cancer | 0.510878 |
|
| free radicals | 0.842716 |
| exogenous antioxidants | 0.527581 |
| Cancer Prevention Trial | 0.559457 |
| alpha-tocopherol supplementation | 0.518828 |
| gastric cancer | 0.506898 |
| skin cancer incidence | 0.521176 |
| antioxidant vitamins | 0.499147 |
| cancer development | 0.495835 |
| total cancer incidence | 0.520828 |
| randomized controlled trial | 0.509347 |
| antioxidant supplementation | 0.554893 |
| antioxidant supplements | 0.754474 |
| prostate cancer | 0.575846 |
| effects | 0.540142 |
| all-cause mortality | 0.510888 |
| et al | 0.922404 |
| New England Journal | 0.537799 |
| cancer risk | 0.507337 |
| lung cancer incidence | 0.528817 |
| cancer | 0.94983 |
| incidence | 0.572134 |
| cancer incidence | 0.567041 |
| long-term beta-carotene supplementation | 0.539474 |
|
CLICK HERE |
| 1861 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de orofaringe (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de orofaringe. |
| Tabor MP | 0.407217 |
| enfermedad oral benigna | 0.333898 |
| antecedentes ganglionares n2b–n3 | 0.348129 |
| nivel v | 0.341116 |
| M0 TX | 0.345233 |
| CA Cancer | 0.341917 |
| squamous epithelium | 0.334337 |
| cirugÃa transoral versus | 0.32767 |
| Cancer Res | 0.419675 |
| clinical implications | 0.349857 |
| DeVita VT Jr | 0.346296 |
| Human papillomavirus infection | 0.357131 |
| VPH tipo | 0.33416 |
| Natl Cancer Inst | 0.562443 |
| enfermedad t4 | 0.338752 |
| nivel ii | 0.349773 |
| neck cancers | 0.968755 |
| human papillomavirus | 0.694615 |
| orofaringe estadio | 0.33767 |
| Head Neck Surg | 0.342719 |
| second primary tumors | 0.391083 |
| Mendenhall WM | 0.327697 |
| Head Neck | 0.399598 |
| estadio iv | 0.354503 |
| M0 T2 | 0.385934 |
|
| M0 T1 | 0.384478 |
| M0 T3 | 0.425033 |
| radioterapia posoperatoria | 0.399508 |
| oral stratified squamous | 0.327772 |
| definiciones tnm | 0.328717 |
| Cancer Staging Manual | 0.397433 |
| múltiples ganglios | 0.776893 |
| cirugÃa versus | 0.380943 |
| Epidemiol Biomarkers Prev | 0.350461 |
| Alto VPH | 0.331071 |
| neck retinoid chemoprevention | 0.329578 |
| oropharyngeal cancers versus | 0.33045 |
| ganglios retrofarÃngeos | 0.460243 |
| Oral Pathol Med | 0.327912 |
| MD Anderson Cancer | 0.350182 |
| index tumor site | 0.345356 |
| field cancerization | 0.375139 |
| ganglios linfáticos retrofarÃngeos | 0.70114 |
| M0 Tis | 0.349862 |
| Braakhuis BJ | 0.34369 |
| oropharyngeal cancer | 0.750404 |
| M0 T4a | 0.419704 |
| neck tumors frequently | 0.331875 |
| AJCC Cancer Staging | 0.401717 |
|
CLICK HERE |
| 1898 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de recto (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de recto. |
| pequeña porción | 0.344303 |
| siguientes procedimientos | 0.488361 |
| estadio iv | 0.798609 |
| siguientes aspectos | 0.39574 |
| ecografÃa transrectal | 0.363875 |
| siguientes tipos | 0.371556 |
| tumor causa obstrucción | 0.365452 |
| rayos x | 0.358514 |
| estadio ivb | 0.576844 |
| enlace drugs approved | 0.373438 |
| menor cantidad | 0.340782 |
| escáner tep | 0.363457 |
| ondas sonoras | 0.360161 |
| estadio iva | 0.572549 |
| información ayuda | 0.344729 |
| recto forma | 0.870609 |
| quimioterapia sistémica | 0.542487 |
| proteÃna llamada factor | 0.366746 |
| National Cancer Institute | 0.340908 |
| recto recidivante | 0.833054 |
|
| cáncer.ampliar colonoscopia | 0.503991 |
| Instituto Nacional | 0.373842 |
| estadio iiia | 0.782206 |
| PDQ Tratamiento | 0.378717 |
| antecedentes familiares | 0.362005 |
| estadio iiic | 0.75767 |
| estadio iiib | 0.767428 |
| estadio iia | 0.790435 |
| siguientes problemas | 0.397252 |
| estadio iic | 0.78747 |
| células cancerosas.El bevacizumab | 0.411094 |
| Physician Data Query | 0.44928 |
| Malestar abdominal | 0.370918 |
| Rectal Cancer | 0.347301 |
| crecer.El ziv-aflibercept | 0.34268 |
| antÃgeno carcinoembrionario | 0.591724 |
| sección cáncer | 0.945618 |
| ano).ampliar extirpación | 0.350725 |
| siguientes sumarios | 0.436031 |
| siguientes pruebas | 0.396087 |
|
CLICK HERE |
| 2041 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de vejiga y otros cánceres uroteliales (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar sistemáticamente el cáncer de vejiga. |
| antecedentes familiares | 0.40081 |
| Schistosoma haematobium | 0.417111 |
| Visuals Online | 0.357081 |
| PDQ Exámenes | 0.503031 |
| Physician Data Query | 0.696072 |
| Estados Unidos | 0.406708 |
| túbulos renales | 0.432914 |
| prevención revisa | 0.368302 |
| sistema urinario masculino | 0.518469 |
|
| largo plazo | 0.406946 |
| vejiga almacena | 0.840919 |
| información ayuda | 0.374743 |
| biopsia.ampliar cistoscopia | 0.431465 |
| National Cancer Institute | 0.400139 |
| siguientes riesgos | 0.364163 |
| pelvis renal | 0.934476 |
| Instituto Nacional | 0.483729 |
|
CLICK HERE |
| 3551 |
National Cancer Institute |
Html |
en |
Cancer Statistics |
Basic information about cancer statistics in the U.S. and how they are used to understand the impact of cancer on society and to develop strategies that address the challenges that cancer poses. |
| cancer statistics | 0.699332 |
| major impact | 0.569457 |
| new screening test | 0.610486 |
| United States | 0.848591 |
| Asian/Pacific Islander women | 0.623563 |
| cancer death rate | 0.734611 |
| cancer deaths | 0.662668 |
| thyroid cancer | 0.618391 |
| SEER program website | 0.613262 |
| renal pelvis cancer | 0.675159 |
| population-based cancer registries | 0.661094 |
| African American men | 0.620993 |
| number | 0.579668 |
| new cancer cases | 0.74726 |
| American Cancer Society | 0.655347 |
| pancreatic cancer | 0.619919 |
| bladder cancer | 0.619451 |
| cancer-related deaths | 0.575865 |
| average age | 0.568157 |
| individual cancer types | 0.652597 |
| North American Association | 0.605716 |
| racial/ethnic group | 0.570832 |
| cancer care | 0.615369 |
| cancer diagnosis | 0.664799 |
|
| breast cancer | 0.617639 |
| rectum cancer | 0.622513 |
| large groups | 0.569141 |
| risk factor | 0.614571 |
| U.S. population | 0.610565 |
| people | 0.571698 |
| statistical trends | 0.613522 |
| age-adjusted mortality | 0.572947 |
| prostate cancer | 0.619132 |
| bronchus cancer | 0.62075 |
| Central Cancer Registries | 0.654709 |
| cancer survivors | 0.603772 |
| cancer mortality | 0.652323 |
| policy makers | 0.566593 |
| Understanding Cancer Prognosis | 0.676403 |
| endometrial cancer | 0.620993 |
| cancer | 0.951216 |
| new cases | 0.679157 |
| cancer incidence | 0.694185 |
| cancer death rates | 0.665983 |
| SEER Cancer Statistics | 0.665479 |
| overall cancer death | 0.735155 |
| cancer rates | 0.609223 |
|
CLICK HERE |
| 14599 |
National Cancer Institute |
Html |
en |
PET-CT–Guided Surveillance May Reduce Need for Surgery in Some Patients with Advanced Head and Neck Cancer |
Patients with advanced squamous cell carcinoma of the head and neck who underwent PET-CT–guided surveillance had fewer operations but similar overall survival rates to those of patients who underwent planned neck dissection. |
| fewer neck dissections | 0.480753 |
| different PET-imaging systems | 0.416156 |
| trial | 0.383529 |
| surgical dissection | 0.49691 |
| surgery group | 0.546725 |
| equivocal response | 0.373027 |
| main goal | 0.370069 |
| standard first-line therapy | 0.446339 |
| 2-year overall survival | 0.421723 |
| results | 0.372041 |
| PET-CT–guided surveillance | 0.384586 |
| PET-CT group | 0.386097 |
| advanced squamous cell | 0.578344 |
| standardized PET imaging | 0.419169 |
| heterogeneous study population | 0.413368 |
| 2,200-per-patient cost savings | 0.413451 |
| study groups | 0.42202 |
| patients | 0.610711 |
| metabolic abnormalities | 0.37096 |
| Dr. Malik | 0.419332 |
| health care costs | 0.414997 |
| lymph nodes | 0.375275 |
| overall survival rates | 0.55552 |
| surveillance group | 0.491325 |
|
| chemoradiation | 0.396529 |
| Shakun Malik | 0.372291 |
| nodal metastases | 0.375714 |
| positron-emission tomography | 0.373068 |
| magnetic resonance imaging | 0.431542 |
| Cancer Research UK | 0.422638 |
| Technology Assessment Programme | 0.42519 |
| United States | 0.41309 |
| N3 disease | 0.374897 |
| fewer operations | 0.382441 |
| randomized controlled PET-NECK | 0.429823 |
| PET-CT imaging | 0.485125 |
| advanced imaging techniques | 0.434786 |
| neck dissection | 0.819668 |
| PET-CT surveillance | 0.497223 |
| neck dissection patients | 0.544115 |
| Hisham Mehanna | 0.370962 |
| long-term results | 0.369928 |
| trial results | 0.371832 |
| United Kingdom | 0.369679 |
| cancer treatment centers | 0.428263 |
| substantial complications | 0.369604 |
| New England Journal | 0.442645 |
| clinical usefulness | 0.371858 |
|
CLICK HERE |
| 16852 |
National Cancer Institute |
Html |
en |
University of California, San Diego — Cancer Research in Nanotechnology (CRIN) |
Provides trainees with a balanced combination comprehensive cancer biology, engineering, and entrepreneurship didactic training, including cancer researcher, clinical/translational cancer faculty, and practical skills in small business environments. |
| synergy | 0.439136 |
| dearth | 0.464725 |
| promise | 0.439416 |
| issues | 0.469099 |
| oral presentations | 0.597869 |
| investigators | 0.43726 |
| San Diego | 0.64989 |
| spite | 0.453494 |
| academia | 0.440105 |
| research advances | 0.635659 |
| academic mentors | 0.611308 |
| Ph.D. | 0.437454 |
| nanotechnology | 0.493685 |
| medical device | 0.611406 |
| cancer therapies | 0.658537 |
| California | 0.440505 |
| engineering/materials science | 0.617993 |
| University | 0.440535 |
| success | 0.436075 |
| comprehensive set | 0.611033 |
| training program | 0.629484 |
| clinical/translational cancer faculty | 0.809173 |
| Current PhD | 0.611308 |
| comprehensive cancer biology | 0.812096 |
| trainees | 0.625803 |
|
| cross training | 0.614905 |
| postdoctoral training | 0.632853 |
| CRIN | 0.480296 |
| cancer research | 0.980901 |
| science cancer researcher | 0.808302 |
| present research proposals | 0.781791 |
| laboratory experience | 0.604598 |
| practical skills | 0.600189 |
| National Cancer Institute | 0.811595 |
| Principal Investigator | 0.635275 |
| young scientists | 0.755823 |
| small firm | 0.611549 |
| cancer. | 0.433521 |
| Dong-Er Zhang | 0.641012 |
| entrepreneurship didactic training | 0.808298 |
| academia. | 0.434053 |
| life. Engineering approaches | 0.803444 |
| Andrew Kummel | 0.630977 |
| application | 0.436257 |
| discoveries | 0.437754 |
| device companies | 0.613133 |
| cancer biology | 0.906785 |
| small business entrepreneurs | 0.772007 |
| academic career path | 0.764024 |
|
CLICK HERE |
| 17292 |
National Cancer Institute |
Html |
es |
Sangrado y moretones (trombocitopenia) |
Información y consejos para controlar el sangrado y los moretones, los cuales son efectos secundarios del tratamiento del cáncer. |
|
|
CLICK HERE |